News
Public · Published
Buy Dixon Technologies; target of Rs 15900: Motilal Oswal
Motilal Oswal reiterated its Buy rating on Dixon Technologies and set a two-year target price of Rs 15,900. The broker reported that quarterly revenue and profit after tax exceeded its estimates, margins were broadly in line, and mobile volumes increased 29% quarter on quarter to 9.7 million.
Published:
Updated:
What happened
Motilal Oswal reiterated its Buy rating on Dixon Technologies and set a two-year target price of Rs 15,900. The broker reported that quarterly revenue and profit after tax exceeded its estimates, margins were broadly in line, and mobile volumes increased 29% quarter on quarter to 9.7 million.
Confirmed
Global impact / market context
The broker’s higher estimates reflect stronger recent performance and expectations for improved volumes from Vivo-JV, exports and new clients, alongside benefits from backward integration, meaning the company makes more components itself. If these gains materialize, they could support revenue and reduce reliance on outside suppliers, but execution and timing matter.
Analyst inference
Dixon’s growth was uneven: mobile volumes increased despite a year-on-year decline in India’s overall smartphone market, while IT hardware and telecom scaled up; non-mobile areas remained weak. The report also notes a slight delay in display backward integration, tempering the expected contribution from that effort.
Confirmed
What to watch
- Check whether mobile volumes continue to grow and whether Dixon sustains market-share gains, since the latest report cites higher volumes even as India’s smartphone market contracted year on year. Analyst inference
- Watch for evidence that display backward integration is completed and contributes in FY28 as the broker expects; delays could postpone cost or operating benefits. Analyst inference
- Track whether Vivo-JV output, exports and new client additions lift FY28 volumes, and whether the IT hardware and telecom businesses continue scaling up. Analyst inference
Evidence
- Original source link unavailable